Analyses of Interleukin-6, Presepsin and Pentraxin-3 in the Diagnosis and Severity of Late-onset Preeclampsia

Cengiz Gokcek Women's and Children's Hospital100 enrolled

Overview

Introduction: The etiology/pathophysiology of preeclampsia remains an enigma. Cellular immunity is a key factor in the etiology of late-onset preeclampsia (L-PrE). Presepsin is split out from the phagocytes membranes after phagocytosis. To investigators knowledge, this is the first study in literature to investigate maternal blood concentrations of presepsin in preeclampsia and healthy pregnant women. Methods: The investigators examined maternal plasma interleukin-6, presepsin and pentraxin-3 concentrations in pregnant women with (n=44) and without L-PrE (n=44). These three inflammatory markers concentrations measured using enzyme-linked immunosorbent assays were compared.

This observational case-control study was designed at Cengiz Gokcek Women's and Children's Hospital, Gaziantep, Turkey, in the Department of Obstetrics and Gynecology between June 2018 and January 2019. The protocol was approved by the Ethics Committee for Clinical Research of Gaziantep University (Reference number: 2018/393). The study strictly adhered to the principles of the Declaration of Helsinki. All subjects included in the study gave oral and written informed consent. Eighty-eight women were enrolled in the study in two groups. All participants will gave their oral and written informed consent before their inclusion in the study.

Study Type

OBSERVATIONAL

Enrollment

100

Conditions

Preeclampsia

Interventions

Eligibility

Sex: FEMALEMin age: 18 YearsMax age: 40 YearsHealthy volunteers:

Medical Language ↔ Plain English

Inclusion Criteria: * preeclampsia healthy pregnancy Exclusion Criteria: 1. pregnant women with any systemic condition (such as chronic hypertension, inflammatory and rheumatic diseases), 2. using any kind of medication throughout pregnancy (such as acetylsalicylic acid, corticosteroids or heparin), 3. pregnant women who had fever at the time of the first admission, 4. concurrent infections (urinary tract infection, cervicitis, etc.), 5. pregnancies complicated with premature membrane rupture or chorioamnionitis, 6. history of medication for PE treatment at the time of the first admission, 7. patients who had fetal congenital abnormalities or genetic syndromes, 8. drug user, 9. multiple gestations, 10. active labor.

Outcomes

Primary Outcomes

The primary endpoint in these analyses was IL-6, presepsin and pentraxin-3 levels in late-onset preeclampsia group and control group.

The primary endpoint in these analyses was IL-6, presepsin and pentraxin-3 levels in late-onset preeclampsia and control group.

Time frame: 3 months